Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

NCT07116967 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

3040

Enrollment

INDUSTRY

Sponsor class

Conditions

Plaque Psoriasis

Interventions

DRUG: Deucravacitinib
DRUG: Ustekinumab

Sponsor

Bristol-Myers Squibb